Introduction
Natural killer (NK) cells are cytolytic cells capable of targeting tumor cells and bacteria-or virus-infected cells. 1 Morphologically, NK cells are lymphoid cells with pale cytoplasm containing azurophilic granules. Developmentally, NK and T cells may share a common bipotential T/NK progenitor cell. Therefore, NK cells express variably T-lineage-associated antigens, including CD2 and sometimes CD7. They are negative for surface CD3, but express cytoplasmic CD3 epsiolon (e) chain. NK cells also express a number of 'NK-associated' antigens, including CD16, CD56 and CD57.
2 CD56 is most consistently expressed, and has been widely regarded as a marker for NK cells. However, CD56 is not specific for NK cells, and can be found on NK-like T-cells, neural and neuroendocrine tissues, and occasionally skeletal muscles. 3 Molecularly, NK cells have germline T cell receptor (TCR) genes, which is different from T cells where the TCR genes are rearranged.
Neoplastic disorders of NK cells
In 1992, two groups described independently lymphoid malignancies that expressed CD56, 4, 5 characterized by a predominant extranodal distribution and an aggressive course. However, the putative NK-cell origin of these tumors was not established initially, because the neoplastic cells were apparently CD3 positive, which led to the diagnosis of a T-cell malignancy. The problem was resolved when it was realized that whereas polyclonal anti-CD3 antibodies bound both surface CD3 and cytoplasmic CD3e, monoclonal anti-CD3 antibodies bound only surface CD3. 6 Therefore, immunohistochemical analysis with polyclonal anti-CD3 antibodies on formalin-fixed paraffin-embedded histologic sections cannot differentiate between T and NK cells (both apparently CD3 positive, T cells for surface CD3; NK cells for cytoplasmic CD3e). However, on frozen or cryostat sections stained with monoclonal anti-CD3 antibodies, NK cells can be differentiated clearly from T cells, with the former negative and the latter positive for surface CD3.
Classifications of NK-cell lymphomas
The World Health Organization (WHO) classification divides NK-cell lymphomas into two histologic categories, NK/T-cell lymphoma, nasal type 7 and aggressive NK-cell leukemia. 8 This is a pathologic classification. In clinical practice, NK-cell lymphomas can be classified into three categories: nasal, nonnasal and aggressive lymphoma/leukemia subtypes, each with different clinical manifestations, treatment approaches and prognosis (Table 1) . 9 NK-cell lymphomas are predominantly extranodal, and lymph node involvement at presentation or subsequently is uncommon. 10 Nasal NK-cell lymphoma Nasal NK-cell lymphomas refer to tumors occurring in the nose and the upper aerodigestive tract. [11] [12] [13] [14] [15] Males are predominantly affected, with the median age of presentation in the fifth decade. The nasal cavity, nasopharynx, paranasal sinuses, tonsils, hypopharynx and larynx may be involved. Symptoms are local, including facial swelling, nasal obstruction and bleeding, proptosis and impairment of extraocular movement. Downward extension of a nasal tumor may result in destruction of the hard palate, leading to the highly characteristic midline perforation, to which the term 'lethal midline granuloma' was once applied (Figure 1 ). 16 
Non-nasal NK-cell lymphomas
Non-nasal NK-cell lymphomas may involve any part of the body. 17 Males are again predominantly affected, with the median age of presentation in the fifth decade. Primary sites include the skin, gastrointestinal tract, salivary glands, spleen and testis. 17 Occasional involvements of muscle 18 and the uterus 19 have been reported. Isolated nodal involvement is highly unusual, and such cases must be carefully evaluated to exclude other CD56-expressing hematolymphoid malignancies. 20 The diagnosis of non-nasal NK-cell lymphoma requires the exclusion of nasal involvement at presentation. A nasal panendoscopy with random biopsies should be performed to exclude occult involvement.
Aggressive NK-cell lymphoma/leukemia
Aggressive NK-cell lymphoma/leukemia is a catastrophic disease. 21, 22 Men and women are equally affected, at a younger median age in the third decade. At presentation, the patient is typically very ill with significant weight loss, jaundice and high fever. Lymphadenopathy may be found with hepatosplenomegaly and sometimes skin infiltration. Severe anemia and thrombocytopenia are common, due to direct marrow infiltration or active hemophagocytosis in the marrow and occasionally the peripheral blood. 21 The white cell count may be increased due to circulating neoplastic cells. Liver function derangement and features of disseminated intravascular coagulopathy are frequent. The clinical progression is inexorable despite treatment. Aggressive NK-cell lymphoma/leukemia is an extremely malignant neoplasm, with the survival measured often just in days to weeks.
Clinical patterns and dissemination of NK-cell lymphomas
Nasal and non-nasal NK-cell lymphomas share similar histopathologic features and are grouped together in the WHO classification.
7 However, they have sufficiently different clinical behaviors and treatment responses to be segregated into two distinct categories. Nasal NK-cell lymphomas are localized. At presentation, they are usually restricted to the nose and upper aerodigestive tract, and distant metastases are infrequent. Marrow involvement occurs in less than 10% of patients. 23 Even in terminal cases, most nasal NK-cell lymphomas remain locally invasive. In contrast, non-nasal NK-cell lymphomas are often multifocal. Distant dissemination occurs early in the clinical course. 17 These different clinical patterns have significant implications on the treatment strategies and prognosis.
Interestingly, when nasal NK-cell lymphomas metastasize, they involve organs that are commonly primary sites of nonnasal NK-cell lymphomas. This phenomenon may be attributed to the expression of CD56, a homotypic molecule facilitating cellular adhesion, 3 on cells of these organs. Aggressive NK-cell Classified as aggressive NK-cell leukemia in the WHO classification.
Figure 1
Nasal NK-cell lymphoma with downward extension and destruction of the hard palate, leading to a communication between the nasal and oral cavities.
lymphoma/leukemia is disseminated at presentation. It is different from a rare terminal leukemic form of nasal and nonnasal NK-cell lymphomas, by the absence of a history of NK-cell malignancies, a younger age at presentation and a very aggressive clinical course.
Histopathology of NK-cell malignancies
The histopathologic features of NK-cell lymphomas are similar irrespective of the involved sites. 7, 8 The lymphoma cells are small to medium in size, although occasionally large and anaplastic forms may be found. Neoplastic cells may be admixed with small lymphocytes, plasma cells, eosinophils and histiocytes. This polymorphic infiltration is distinct from the monotonous cellular infiltrate found in conventional B-cell lymphomas, leading to the older terminology 'polymorphic reticulosis'. The infiltrates may be diffuse, or show angiocentricity and angiodestruction, accounting for the diagnosis of angiocentric T-cell lymphoma as proposed in the Revised European and American Classification. 24 Owing to angiodestruction, coagulative necrosis and apoptotic bodies are frequent. In aggressive NK-cell lymphoma/leukemia, circulating lymphoma cells varying from large granular lymphocytes to frank blasts may be found. 21 Marrow infiltration is patchy. Tissue infiltration by aggressive NK-cell lymphoma/leukemia shows features comparable with other NK-cell lymphomas.
Immunophenotypically, NK lymphoma cells are typically positive for CD2, cytoplasmic CD3e and CD56. Other T-and NK-cell markers are usually negative. The expression of cytotoxic molecules, including perforin, granzyme B and TIA-1, and the presence of Epstein-Barr virus (EBV) infection, as shown by in situ hybridization (ISH) for EBV-encoded early small RNA (EBER), are important ancillary features. 7 The typical phenotype of CD2 þ , CD3e þ , CD56 þ , cytotoxic molecule þ and EBV þ is usually shown in non-nasal NK-cell lymphomas and aggressive NK-cell lymphoma/leukemia and poses no specific problems. However, in nasal lymphomas, rare cases might be CD2 þ , CD3e þ , cytotoxic molecule þ , EBV þ but CD56-, and exceptional ones might show TCR gene rearrangement. These cases are too infrequent to determine if they are clinically or biologically similar to the majority of nasal NK-cell lymphomas, leading to their provisional inclusion as the 'T-cell' part of the WHO nomenclature of NK/T-cell lymphoma. In clinical practice, NK-cell lymphoma is still the preponderant subtype, and contemplation of a possible T-cell origin is rarely necessary for nasal lymphomas. Finally, it must be noted that cases which are CD3e þ but negative for cytotoxic molecules or EBV should be diagnosed as peripheral T-cell lymphoma, unspecified. 7 Epidemiologic features NK-cell lymphomas have a distinctive geographic distribution. They are reported mostly from Asians and South Americans. 7, 8 Other than isolated cases, well-documented series from white populations have not been described. The exact prevalence of NK-cell lymphomas was affected previously by the confusion between T-and NK-cell lymphomas. Consequently, T-cell lymphomas were regarded inappropriately to constitute up to 25% of all lymphomas in Asia. 25 When WHO classification criteria were strictly adhered to, a recent study of a Chinese population 26 showed that T-cell lymphomas accounted for only 10% of all lymphomas, an incidence similar to that in Western patients. The incidence of NK-cell lymphomas was found to be about 6%. Therefore, the decline in the incidence of T-cell lymphomas observed recently in Asian populations is due to better recognition of NK-cell lymphomas as a distinct clinicopathological entity.
EBV infection of NK lymphoma cells
The pathogenesis of NK-cell lymphomas remains ill-defined. However, a consistent finding is EBV infection in the lymphoma cells, observed in Asian, European and South American patients. 21, [27] [28] [29] [30] Analysis of the EBV terminal repeat region shows the presence of a clonal episomal form. 31 This implies that EBV is etiologically important and not merely a bystander. The presence of EBV has important clinical implications. ISH for EBER accurately identifies NK lymphoma cells in histopathologic sections. 32 The test is particularly informative in sites where EBV is usually absent, such as the liver and bone marrow. Thus, the presence of EBER-positive cells in liver or marrow biopsies in a patient with NK-cell lymphoma is strong evidence of lymphoma involvement. 32 
Staging of NK-cell lymphomas
The Ann-Arbor staging system, based on contiguous lymphatic spread and designed for Hodgkin's lymphoma, is problematic for NK-cell lymphomas. As in other extranodal lymphomas, the Ann-Arbor staging does not take into account the tumor size, an important determinant in locally invasive tumors. Therefore, nasal NK-cell lymphomas involving extensively the nasal cavity, paranasal sinuses and nasopharynx would still be considered as stage I E disease. 21, 11, [33] [34] [35] [36] [37] [38] [39] To overcome this problem, a staging system devised originally for conventional sinonasal B-cell lymphomas 40 has been tested in nasal NK-cell lymphomas. Initial results showed that stage T1/T2 diseases had superior outcome compared with stage T3/T4 diseases. 41 The International Prognostic Index (IPI), which considers not only the stage but also the age, performance status and the lactate dehydrogenase (LDH) level, 42 has also been found to be prognostically relevant in nasal NK-cell lymphomas. 15 A staging system combining the tumor size, the Ann-Arbor staging and IPI may be more appropriate and remains to be validated.
Quantification of circulating plasma EBV DNA
The quantification of plasma EBV DNA is useful in predicting the occurrence and treatment response in EBV-associated posttransplantation lymphoproliferative diseases (PTLD). The increase in EBV DNA is attributed to lytic EBV reactivations during severe immunosuppression. In EBV-associated lymphoid malignancies in immunocompetent hosts, circulating EBV DNA is also increased. 43 A possible mechanism is tumor release of EBV DNA, owing to apoptosis of proliferating tumor cells. 44 Serial quantification of circulating plasma EBV DNA have indeed correlated with disease status in NK-cell lymphomas. 45 Circulating EBV DNA is increased invariably before treatment, from 10 5 to 10 10 copies/ml. At presentation, EBV DNA correlates with the clinical staging and the LDH level, implying that it is a useful surrogate tumor biomarker in the initial evaluation of NK-cell malignancies.
Radiotherapy of NK-cell lymphomas
Radiotherapy is an important treatment modality for stage I/II nasal NK-cell lymphomas. The overall response rate ranged from 60 to 80%, complete remission (CR) rate 40 to 80% and 5-year overall survival (OS) 40 to 59% (Table 2) . 14, [33] [34] [35] [36] 38, 39, 46, 47 Typically, a total dose of 30-60 Gy is administered. Computerized tomographic or magnetic resonance imaging scans should be used to determine the radiation target volumes.
Despite high initial response rates, relapse are frequent, varying from 17% 38 to 77%, 39 with 50% being most commonly reported. 14, 48 Radiotherapy failures can be divided into in-field failures, margin failures and systemic recurrences. Factors that contribute to local relapses include dosages of less than 45 39 to 50 Gy, 48 and radiotherapy planning not assisted by radiologic imaging. 48 Most local failures happen within the first year, and recurrences after 2 years are very uncommon. 14, 48 Systemic failure occurs in 25-30% of patients treated with radiotherapy alone. 14, 48, 37, 38 More than half of the systemic relapses are not associated with local recurrences, indicating that many apparently early-stage patients have in fact more disseminated diseases. Consequently, an important issue is how patients with more widespread disease can be recognized, and whether the addition of chemotherapy will improve the outcome. However, none of the studies reported so far have been successful in identifying risk factors for systemic relapses. Therefore, a continuous search for better disease indicators, such as the tumor volume and innovative molecular or surrogate tumor biomarkers, will be needed to improve the stratification for treatment.
Non-nasal NK-cell lymphomas are usually advanced at presentation, and early-stage diseases disseminate rapidly. Therefore, radiotherapy is only used in adjunctive or palliative situations.
Chemotherapy of NK-cell lymphomas
Chemotherapy is the mainstay of treatment for stage III/IV nasal NK-cell lymphoma. Furthermore, chemotherapy is also advocated as part of the regimen for stage I/II disease, owing to high relapse rates after radiotherapy. 10 Hence, for medically fit patients with nasal NK-cell lymphomas, chemotherapy should be part of the treatment protocol. Age is the most important factor influencing the choice of chemotherapy. Anthracyclinecontaining regimens have traditionally been used, although there is no evidence to show that anthracyclines are essential.
For stage I/II nasal NK-cell lymphomas, primary chemotherapy gives CR rates of 40-60%. 21, 48, 37, 38 Disease progression during chemotherapy occurs in the other 30-40% of patients, 48, 37 necessitating the use of salvage radiotherapy, as alternative chemotherapeutic regimens are usually ineffective. Furthermore, 30-40% of patients achieving CR after chemotherapy will relapse. Therefore, the overall failure rate of chemotherapy reaches 67%. 10, 48 The high failure rate of chemotherapy may be due to expression of the multidrug resistance (MDR) gene (P-glycoprotein). Actually, of all hematolymphoid cells, NK cells express the highest levels of P-glycoprotein. 49 Accordingly, P-glycoprotein expression has been found frequently in NK lymphoma cells. 
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For stage III/IV nasal tumors, non-nasal tumors at any stage, and aggressive lymphoma/leukemia, chemotherapy is the only choice of treatment. CR rates for stage III/IV nasal and non-nasal tumors are less than 15%. 11, 21 Conventional chemotherapy for aggressive NK-cell lymphoma/leukemia results in few if any responses.
Relative merits of radiotherapy and chemotherapy in early-stage nasal NK-cell lymphomas Although radiotherapy has not been compared formally with chemotherapy, most observational studies have consistently shown radiotherapy to be superior to chemotherapy alone in stage I/II disease. 33, 39, 40 Furthermore, nasal NK-cell lymphomas not responding to chemotherapy can be salvage by radiotherapy in about 50% of cases. In contrast, patients failing radiotherapy respond minimally to salvage chemotherapy. 48, 38, 39 Therefore, for stage I/II nasal NK-cell lymphomas, chemotherapy alone is not the ideal treatment. Radiotherapy, either as the initial treatment or as part of the chemotherapy regimen, is the single most important key to successful outcome. 10 
Prognostic factors of NK-cell lymphomas
The IPI has been shown to predict outcome in nasal NK-cell lymphomas. In a study of 67 patients, 15 irrespective of whether the primary treatment was radiotherapy or chemotherapy, patients with IPIp1 were superior to those with IPIX2 for 20-year OS. Subgroup analysis of patients treated with intensive chemotherapy followed by involved-field radiotherapy also showed that patients with IPIp1 were superior to those with IPIX2 for CR rate and 10-year OS.
Quantification of circulating EBV DNA is also prognostically relevant. 46 In 23 patients with various NK-cell lymphomas, multivariate analysis including the presentation EBV DNA, stage, age and LDH level showed that presentation EBV DNA was the only significant factor, with a load of 46.1 Â 10 7 copies/ml negatively impacting on disease-free survival (DFS).
For early-stage nasal NK-cell lymphoma, prognostication is important, as some patients may be curable with radiotherapy and conventional chemotherapy, while others may require additional or innovative therapy. Prospective studies are needed to investigate whether a combination of local tumor staging, IPI score and plasma EBV DNA load may provide a better guide to treatment.
No survival has been reported for aggressive NK-cell lymphoma/leukemia treated with conventional chemotherapy. 19, 21 The use of allogeneic hematopoietic stem cell transplantation (HSCT) had been described to result in remission in a few patients, although whether long-term survival could be achieved was unknown. 51, 52 Non-nasal NK-cell lymphomas fare marginally better, with long-term remission reported in less than 10% of cases.
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Disease monitoring after treatment NK cells lack a clonal marker, making molecular analysis for residual disease difficult. Surrogate tumor biomarkers for disease monitoring have been explored. Frequent aberrant promoter methylation leading to gene silencing has been found in NK-cell lymphomas. 53 The genes implicated include p73, retinoic acid receptor b and death-associated protein kinase. With the methylation-specific polymerase chain reaction (MSP), which has a sensitivity of 10 À3 of detecting the methylated allele, aberrant methylation has been shown to be more sensitive than morphologic or immunophenotypic examination for detecting minimal residual lymphoma. 54 To adopt this strategy, a panel of genes is tested for aberrant methylation in the primary tumor. When a follow-up biopsy is taken, the MSP is used to detect aberrant methylation, which reflects indirectly the presence of lymphoma cells.
Circulating biomarkers may also correlate with the lymphoma load. Soluble Fas-ligand is secreted by NK cells, and circulating soluble Fas-ligand levels might be increased in neoplastic proliferation of NK cells. 55 Soluble Fas-ligand was found to be significantly increased in aggressive NK-cell lymphoma/leukemia, but undetectable in patients in remission. 56 However, these results have not been confirmed, as a reliable enzyme-linked immunosorbent assay for Fas-ligand is not available. The level of the metastases suppressor protein nm23-H1 was also found to be significantly increased in NK-cell lymphomas, and correlated with nonremission, poor 10-year OS and unfavorable IPI. 57 Whether it is useful in patient follow-up has not been validated.
Circulating EBV DNA has been shown to be more robust in disease monitoring. 45 During treatment, a decrease in EBV DNA correlates with clinical control of the lymphoma. Achievement of CR is associated with undetectable EBV DNA. Accordingly, patients who at any stage of their disease show EBV DNA levels exceeding those at presentation (indicating lymphoma progression), or who fail to achieve undetectable EBV DNA (signifying failure to reach CR) have an inferior prognosis. The test may be useful in deciding whether patients reaching a remission should receive extra treatment. Patients in apparent CR who have high levels of circulating EBV DNA will invariably relapse, and should therefore require additional or innovative therapy.
HSCT in NK-cell lymphomas
Since marrow involvement is uncommon, autologous HSCT (auto-HSCT) is potentially applicable to most patients. Indications include stage I/II disease in first CR (CR1), CR2 or chemotherapy-sensitive relapse, and primary or secondary refractory disease with uninvolved marrow. In the largest series of auto-HSCT reported to date, 58 over 70% of patients transplanted at CR1 after conditioning with cyclophosphamide, carmustine and etoposide had remained in remission, at a median follow-up of about 2 years. Although this might appear superior to radiotherapy or chemotherapy, all auto-transplanted patients had stage I disease and were highly selected. In fact, a comparison of these patients with a historical control group of stage I/II patients treated with chemotherapy and/or radiotherapy in the same study failed to show a significant difference in DFS and OS. As a definite advantage has not been established, auto-HSCT for stage I/II disease at CR1 should not be routinely recommended outside the context of a clinical trial.
Auto-HSCT beyond CR1 is associated with poor results.
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Patients auto-transplanted at CR2, chemotherapy-sensitive first relapse not yet reaching CR2, or uncontrolled primary disease or relapse, had consistently poor outcome and virtually no longterm survival. Failure in these patients was usually due to disease progression at the sites involved prior to HSCT, implying that the conditioning was ineffective. Hence, before an optimal conditioning regimen can be defined, patients in these situations may not benefit from auto-HSCT, and should be offered experimental or innovative treatment.
With the role of auto-HSCT uncertain, allogeneic HSCT becomes an appealing option. 59, 60 The additional advantage of allogeneic HSCT is a potential graft-versus-lymphoma effect. This is particularly relevant, as NK lymphoma cells express EBV antigens that may be allo-reactive targets. Only a limited number of patients undergoing allogeneic HSCT have been reported. 59, 60 In a retrospective questionnaire study of 28 patients with NK-cell malignancies undergoing allogeneic HSCT, an OS of 40% was reported after a median follow-up of 34 months. 60 Factors positively affecting survival included age o 40 years and the use of peripheral blood HSC for transplantation. The few cases described and a possible reporting bias prevents a full appraisal of allogeneic HSCT in NK-cell lymphomas, so that more studies are needed.
Additional treatment options for refractory NK-cell lymphomas
The possibility of MDR in NK-cell lymphoma has led to the investigation of agents unaffected by P-glycoprotein. The drug L-asparaginase has been reported to be effective in refractory diseases. [61] [62] [63] L-asparaginase depletes asparagines, and as lymphoid cells lack L-asparagine synthetase, they are susceptible to L-asparaginase-induced inhibition of protein, DNA and RNA synthesis. At 6000 U/day for 7 days, L-asparaginase induced a CR in a case of relapsed non-nasal NK-cell lymphoma. 63 Together with vincristine and steroids, L-asparaginase (4000-6000 U/day for 7 days) was reported to lead to CR in 56% of patients with nasal NK-cell lymphoma. 62 Common side effects included allergic rashes, liver function derangement and hyperglycemia. The long-term outcome of L-asparaginase treatment has not been reported, so that its role in NK-cell malignancies remains to be defined.
Molecular pathology of NK-cell lymphomas
Cytogenetic investigations of NK-cell lymphoma/leukemia had shown deletion of the long arm of chromosome 6 (6qÀ) as a consistent aberration. 64 Furthermore, 6q-had also been localized to CD3ÀCD56 þ lymphoma cells, 65 confirming that the chromosomal aberration was restricted to neoplastic NK cells. A commonly deleted region in chromosome 6q21 to 6q25 had been defined by fluorescence ISH and molecular genetic methods, 66, 67 Comparative genomic hybridization and loss of heterozygosity studies had shown that, in addition to 6q-, deletions in chromosomes 11q, 13q and 17p were also present. 68, 69 The putative genes implicated in these deletions have not been identified.
Involvement of specific genes has not been extensively investigated in NK-cell lymphomas. An early study showed frequent mutations of the c-kit gene. 70 However, this finding has not been confirmed independently. Epigenetic inactivation by promoter hypermethylation of multiple genes has been observed. 53, 71 Partial deletion of the Fas gene at the death and transmembrane domains was found in some cases, which disrupted the Fas-ligand/Fas signaling pathway, thereby protecting the lymphoma cells from apoptosis. 72 The relative roles of these genetic aberrations in NK-cell lymphomagenesis remain to be further defined.
Recurrences of NK-cell lymphomas after prolonged remissions
In nasal and non-nasal NK-cell lymphomas, relapses usually occur within 2 years of CR. However, exceptional patients have been reported to relapse from 29 15 to as long as 38 years 73 after initial remission. This prolonged remission before relapse is not consistent with the aggressive nature of the lymphoma, raising the contention that the relapse might in fact be a new lymphoma. A possible model is the existence of a pool of NK cells chronically infected with EBV. The EBV infection may provide the initial steps of transformation, with additional genetic events necessary for lymphomagenesis. After eradication of the first lymphoma, gradual accumulation of mutations leads to the formation of a second lymphoma from this pool of EBV-infected NK cells. Such a proposition requires validation by future studies.
PTLD of NK-cell lineage
Rare cases of PTLD of NK-cell lineage have been described after solid organ allografting. [74] [75] [76] Whether this reflects chance occurrence or the opportunistic neoplastic proliferation of EBV-infected NK cells is uncertain. None of the reported cases responded to anti-EBV therapy or immunosuppression withdrawal. Thus, NK-PTLD should receive the same treatment as de novo NK-cell lymphomas.
Chronic active EBV infection
Chronic active EBV infection is a rare condition, characterized by high circulating EBV DNA loads and proliferation of EBVinfected T or NK cells. 77 Transformation to NK-cell lymphoma may occur. 78 Therapy with autologous EBV-specific cytotoxic T cells has been reported to be effective. 79 However, overall treatment results are poor, although occasional success has been reported after allogeneic HSCT. 80 Blastic NK-cell lymphoma/CD4 þ CD56 þ hematodermic neoplasm Blastic NK-cell lymphoma was previously regarded by the WHO classification as a distinct pathologic entity. 81 In the recent WHO-EORTC classification, 82 however, they are referred to CD4 þ /CD56 þ hematodermic neoplasm. This reflects the current belief that the neoplastic cells are not derived from NK cells, but from plasmacytoid dendritic cells. This neoplasm is markedly different from NK-cell malignancies. There is no racial predilection, and older patients are affected. Histologically, there is a monotonous dermatologic infiltration without epidermotropism. Angioinvasion/angiodestruction and necrosis are absent. The neoplastic cells express CD4 and CD56, and variably CD2 and CD7. Cytoplasmic/surface CD3, cytotoxic proteins and EBV are negative. The optimal therapy is unclear, although treatment protocols for acute leukemia may give better responses than those for lymphomas. 83 Research directions and perspectives NK-cell malignancies have a predilection to Asian and South American populations. The definition of this genetic predisposition should have important implications in diagnosis, research and treatment. Owing to the unsatisfactory results of conventional treatment, the potential use of biologic agents active against lymphoid malignancies, such as purine analogs and monoclonal antibodies, needs to be explored. Although NK-cell lymphomas are considered frequent in Asian countries, they only account for 6-7% of all lymphomas. 26 Therefore, international collaborative studies are required to advance the knowledge of this interesting lymphoma.
